| scholarly article | Q13442814 |
| P50 | author | Arne Yndestad | Q65017091 |
| Tom Eirik Mollnes | Q73118485 | ||
| Geir Øystein Andersen | Q114371067 | ||
| Trygve Husebye | Q114454750 | ||
| Pål Aukrust | Q47504859 | ||
| Peter Garred | Q59433407 | ||
| P2093 | author name string | Ingebjørg Seljeflot | |
| Andreas Barratt-Due | |||
| Guro Grindheim | |||
| Per H Nilsson | |||
| Hilde L Orrem | |||
| Søren E Pischke | |||
| P2860 | cites work | Structural insights into the innate immune recognition specificities of L- and H-ficolins | Q24682124 |
| The danger model: a renewed sense of self | Q28214633 | ||
| The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels | Q28294974 | ||
| Innate immunity: the virtues of a nonclonal system of recognition | Q29614428 | ||
| Complement and its role in innate and adaptive immune responses | Q34088142 | ||
| Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. | Q34179243 | ||
| Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure | Q34498176 | ||
| Complement analysis in the 21st century | Q34674625 | ||
| Association of ficolin-3 with severity and outcome of chronic heart failure | Q34676160 | ||
| Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome | Q34988829 | ||
| The inflammatory response in myocardial injury, repair, and remodelling. | Q35529656 | ||
| The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats | Q36270882 | ||
| The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification | Q63728042 | ||
| Serum complement activation in congestive heart failure | Q73687851 | ||
| The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation | Q81009325 | ||
| Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure | Q83531146 | ||
| Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study | Q85840304 | ||
| Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases | Q36573005 | ||
| Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. | Q36665443 | ||
| Cardiogenic shock: current concepts and improving outcomes | Q37077213 | ||
| Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin | Q37430921 | ||
| MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement | Q37510203 | ||
| Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States | Q37648570 | ||
| Cardiogenic shock: the role of inflammation | Q37805473 | ||
| Role of complement and perspectives for intervention in ischemia-reperfusion damage. | Q37831329 | ||
| The innate immune response in reperfused myocardium | Q37977824 | ||
| Inflammatory cytokines in heart failure: mediators and markers | Q38018808 | ||
| The complement system in ischemia-reperfusion injuries | Q38042217 | ||
| An international serum standard for application in assays to detect human complement activation products | Q38115914 | ||
| Management of cardiogenic shock | Q38366956 | ||
| Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention | Q38376259 | ||
| New insights into the role of ficolins in the lectin pathway of innate immunity | Q38389566 | ||
| Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial | Q38400764 | ||
| Systemic inflammatory response following acute myocardial infarction | Q38531965 | ||
| A journey through the lectin pathway of complement-MBL and beyond | Q38558930 | ||
| Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state | Q40015050 | ||
| Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention Analyzed by Age Groups (<75, 75 to 85, and >85 Years); (Results from the Bremen STEMI Registry). | Q40280637 | ||
| Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment | Q40684844 | ||
| Ficolin-1 is present in a highly mobilizable subset of human neutrophil granules and associates with the cell surface after stimulation with fMLP. | Q43278864 | ||
| Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial | Q43777913 | ||
| Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. | Q45302529 | ||
| Mannose binding lectin acute phase activity in patients with severe infection | Q46679835 | ||
| C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction | Q47191457 | ||
| Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association | Q47942317 | ||
| Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy | Q47957724 | ||
| Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myoc | Q57483220 | ||
| Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarction—A magnetic resonance study | Q63728000 | ||
| Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation | Q63728017 | ||
| P433 | issue | 3 | |
| P921 | main subject | heart failure | Q181754 |
| cardiogenic shock | Q2477062 | ||
| acute decompensated heart failure | Q4677930 | ||
| P304 | page(s) | 292-301 | |
| P577 | publication date | 2018-02-09 | |
| P1433 | published in | ESC Heart Failure | Q27727376 |
| P1476 | title | Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock | |
| P478 | volume | 5 |
Search more.